The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report.

MLA

Del Re, Marzia, et al. “The Increase in Activating EGFR Mutation in Plasma Is an Early Biomarker to Monitor Response to Osimertinib: A Case Report.” BMC Cancer, vol. 19, no. 1, Apr. 2019, p. 410. EBSCOhost, https://doi.org/10.1186/s12885-019-5604-6.

APA

Del Re, M., Rofi, E., Cappelli, C., Puppo, G., Crucitta, S., Valeggi, S., Chella, A., Danesi, R., & Petrini, I. (2019). The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report. BMC Cancer, 19(1), 410. https://doi.org/10.1186/s12885-019-5604-6

Chicago

Del Re, Marzia, Eleonora Rofi, Carla Cappelli, Gianfranco Puppo, Stefania Crucitta, Simona Valeggi, Antonio Chella, Romano Danesi, and Iacopo Petrini. 2019. “The Increase in Activating EGFR Mutation in Plasma Is an Early Biomarker to Monitor Response to Osimertinib: A Case Report.” BMC Cancer 19 (1): 410. doi:10.1186/s12885-019-5604-6.